EkoSonic™ Endovascular System
EKOS was the first product indicated for the treatment of pulmonary embolism. The EkoSonic catheter can be used for the infusion of physician selected therapeutics, including thrombolytics for the treatment of diseases, such as deep vein thrombosis and arterial occlusion.
Acoustic Pulse Thrombolysis™
- Speeds time-to-clot dissolution.
- Results in quality clinical outcomes.
- Increases clot removal and enhances clinical improvement compared to either standard catheter-directed drug therapy or thrombectomy.1,2
- Requires significantly shorter treatment times compared to standard CDT.3
Targets the Thrombus Safely
- Lowers the risk of bleeding and other complications.1,4
- Dissolves clots without damaging vessels, valves or walls.5
More Effective Drug Delivery
- Reduces dosage requirements by as much as 68% compared to standard, catheter-directed drug therapy.1
- Requires up to 4x less drug dosage than traditional systemic delivery.6,7
- Reduces RV/LV ratio with as little as 8mg total tPA used in combination with EKOS therapy.8
Superior Clot Clearance3,7
- 48% greater drug absorption within 1 hour.9
- 84% greater drug absorption within 2 hours. 9
- Lin, P., et al., Vasc, Vol. 17, Suppl. 3, 2009, S137-S147.
- Lin, P., et al., Perspectives in Vasc Surg and Endo Ther, 2010, 22(3):152-163.
- Litzendorf, M., et al., SVS 2011 Abstract RR20.
- Parikh, S., et al., J Vasc Interv Radiol, Vol. 19, Issue 4, April 2008, 521–528.
- Soltani, A et al. Ultrasonics 2007; 46:60-67.
- Kucher, N., et al., Circulation, Vol. 129, No. 4, 2014, 479–486.
- Piazza, G., et al., JACC: Cardiovasc Intervent 2015; 8(10): 1382-92.
- Tapson, Victor, et al., “A Randomized Trial of the Optimum Duration of Acoustic Pulse Thrombolysis Procedure in Acute Intermediate-Risk Pulmonary Embolism: The OPTALYSE PE Trial.” JACC: Cardiovascular Interventions Jul 2018, 11 (14) 1401-1410.
- Francis, C.W., et al., Ultrasound in Medicine and Biology, 21.3, 1995, 419–424.